These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1387016)

  • 21. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
    Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
    Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Helper strategy in tumor immunology: expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy.
    Forni G; Fujiwara H; Martino F; Hamaoka T; Jemma C; Caretto P; Giovarelli M
    Cancer Metastasis Rev; 1988 Dec; 7(4):289-309. PubMed ID: 2974763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.
    Iwai Y; Ishida M; Tanaka Y; Okazaki T; Honjo T; Minato N
    Proc Natl Acad Sci U S A; 2002 Sep; 99(19):12293-7. PubMed ID: 12218188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regression of established tumors in mice mediated by the oral administration of a recombinant Listeria monocytogenes vaccine.
    Pan ZK; Ikonomidis G; Pardoll D; Paterson Y
    Cancer Res; 1995 Nov; 55(21):4776-9. PubMed ID: 7585503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses.
    Fujiwara H; Yoshioka T; Shima J; Kosugi A; Itoh K; Hamaoka T
    J Immunol; 1986 Apr; 136(7):2715-9. PubMed ID: 3005417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccination therapy with tumor-dendritic cell hybrids: a promising therapeutic approach?
    Haenssle HA
    Curr Opin Investig Drugs; 2005 Dec; 6(12):1240-5. PubMed ID: 16370389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytotoxic T lymphocyte therapy of cancer and tumor escape mechanisms.
    Melief CJ; Kast WM
    Semin Cancer Biol; 1991 Oct; 2(5):347-54. PubMed ID: 1773050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ovarian tumour antigens as potential targets for immune gene therapy.
    Kuiper M; Peakman M; Farzaneh F
    Gene Ther; 1995 Jan; 2(1):7-15. PubMed ID: 7712335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
    Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
    J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Augmentation of antitumor immune response by trinitrophenyl (TNP)-reactive helper T-cells: enhanced induction of tumor-specific Lyt-1+2- T-cell-mediated delayed-type hypersensitivity from spleen cells of tumor-bearing mice by TNP helpers.
    Suda T; Fujiwara H; Mizushima Y; Shearer GM; Hamaoka T
    J Natl Cancer Inst; 1986 Dec; 77(6):1267-72. PubMed ID: 2948049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transfer.
    Song K; Chang Y; Prud'homme GJ
    Gene Ther; 2000 Mar; 7(6):481-92. PubMed ID: 10757021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity.
    Bannerji R; Arroyo CD; Cordon-Cardo C; Gilboa E
    J Immunol; 1994 Mar; 152(5):2324-32. PubMed ID: 7907636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide.
    van Bergen J; Camps M; Offringa R; Melief CJ; Ossendorp F; Koning F
    Cancer Res; 2000 Nov; 60(22):6427-33. PubMed ID: 11103809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1alpha expression.
    Voronov E; Weinstein Y; Benharroch D; Cagnano E; Ofir R; Dobkin M; White RM; Zoller M; Barak V; Segal S; Apte RN
    Cancer Res; 1999 Mar; 59(5):1029-35. PubMed ID: 10070959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy of murine and human tumors in mice with lymphokines and interleukin-2-propagated lymphocytes.
    Kedar E; Chriqui-Zeira E; Kyriazis AP
    J Biol Response Mod; 1984 Oct; 3(5):517-26. PubMed ID: 6334139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular research in cancer: future clinical applications.
    Ratliff TL
    Acta Urol Belg; 1996 May; 64(2):53-5. PubMed ID: 8701813
    [No Abstract]   [Full Text] [Related]  

  • 37. The N-terminal flanking region of the invariant chain peptide augments the immunogenicity of a cryptic "self" epitope from a tumor-associated antigen.
    Hess AD; Thoburn C; Chen W; Miura Y; Van der Wall E
    Clin Immunol; 2001 Oct; 101(1):67-76. PubMed ID: 11580228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts.
    Gabrilovich DI; Ciernik IF; Carbone DP
    Cell Immunol; 1996 May; 170(1):101-10. PubMed ID: 8665590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antigen presentation by B7-nonprofessional APC does not prevent responses to solid tumor cells.
    Salvadori S; Moran T; Zier K
    Cell Immunol; 1998 Jan; 183(1):52-9. PubMed ID: 9578719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The structure and function of MHC molecules. Possible implications for the control of tumor growth by MHC-restricted T cells.
    Kourilsky P; Jaulin C; Ley V
    Semin Cancer Biol; 1991 Oct; 2(5):275-82. PubMed ID: 1773044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.